Veligrotug is a medicine used to treat thyroid eye disease, which can make the eyes bulge, swell and see double. It is given as an infusion into a vein. It works by blocking a signal that drives the swelling of tissue behind the eyes.
Every report comes from a Lived member, sent anonymously.
Have you tried Lumvoa (Veligrotug) for Graves Eye Disease?
Veligrotug, sold under the brand name Lumvoa, is a prescription infusion medicine for thyroid eye disease. In this autoimmune condition, the immune system inflames the tissue around and behind the eyes. The swelling can push the eyes forward so they bulge (called proptosis), cause double vision, and make the eyelids puffy, red or sore. Most people who develop it also have an overactive thyroid, usually from Graves' disease. The US Food and Drug Administration approved veligrotug in June 2026 for thyroid eye disease whether it is in its early, actively inflamed phase or has been present for a long time (the chronic phase). It belongs to the same drug type as Tepezza (teprotumumab), an earlier medicine for this condition, but is given as a shorter course. It was studied in adults; its safety and effectiveness in children have not been established.
Veligrotug is a monoclonal antibody, a lab-made protein designed to attach to one specific target. Its target is the insulin-like growth factor-1 receptor (IGF-1R), a receptor on the surface of cells that passes along growth and activity signals. By attaching to IGF-1R, veligrotug keeps those signals from switching on. In thyroid eye disease, blocking this receptor leads to less swelling behind the eyes, less bulging and less double vision, although researchers have not fully worked out why. The same signaling is needed for a developing baby and the placenta, which is why the medicine is not used during pregnancy.
Veligrotug is given as an intravenous (IV) infusion at an infusion center or clinic, once every three weeks for a total of five infusions, so the full course takes about 12 weeks. The dose is calculated from body weight. The first infusion runs over about 45 minutes; if it goes smoothly, later infusions can run over about 30 minutes. It is a set course rather than an ongoing medicine. For comparison, Tepezza is given as eight infusions on the same three-week schedule, each lasting 60 to 90 minutes. Before the first infusion, expect a hearing test, a blood sugar check and, for anyone who could become pregnant, a pregnancy test.
Muscle spasms or cramps are the most common side effect, reported by about 40% of people in the trials compared with 7% on placebo (an inactive infusion). Headache, tiredness, diarrhea, nausea, dry skin and higher blood pressure were also more common than with placebo. About 29% of people who menstruate noticed changes such as missed, delayed, irregular or painful periods. Some people noticed hair thinning or brittle nails in the months after the course. Hearing changes and higher blood sugar are also among the more frequent effects and are explained with the warnings below. About 9% of people had an infusion reaction, such as a temporary rise in blood pressure, fever, chills, headache or tiredness during or soon after an infusion. These reactions were usually mild or moderate. Tell the infusion staff right away if you feel unwell during an infusion, and contact the care team promptly if these symptoms start after you leave. Later infusions can be given more slowly or with medicines beforehand to prevent a repeat.
Veligrotug can cause hearing problems, including severe hearing loss that is sometimes permanent. In the trials, about 15% of people on veligrotug had hearing symptoms such as ringing in the ears, muffled hearing, a plugged feeling or hearing their own voice unusually loudly, compared with 6% on placebo. Hearing is checked before, during and after treatment, and any change in hearing should be reported to the care team. People with existing hearing loss or ear disease were left out of the main studies, so they should weigh this risk with their doctor before starting. The medicine can raise blood sugar. This happened in about 12% of trial participants, and half of them already had diabetes or prediabetes. Diabetes should be well controlled before starting, blood sugar is checked during the course, and diabetes medicines may need adjusting. Veligrotug can trigger or worsen inflammatory bowel disease (IBD), the group of conditions that includes Crohn's disease and ulcerative colitis, even in people never diagnosed with it. Contact the care team right away for diarrhea, especially with blood, for rectal bleeding, or for belly cramping with an urgent need to go. If IBD is suspected, treatment is stopped. Veligrotug may harm a developing baby and should not be used during pregnancy. People who could become pregnant need a pregnancy test before starting and effective birth control during treatment and for 6 months after the last infusion. There is no information yet on use while breastfeeding. The label lists no specific drug interactions, but the prescriber should still see a full list of medicines and supplements.
Some people notice less eye bulging or double vision within the first few weeks; in the main trial for active disease, improvement was seen as early as week 3. Results are formally judged at the end of the course. In that trial, 70% of people on veligrotug had their eye bulging reduced by at least 2 millimeters, measured with a small ruler-like instrument called an exophthalmometer, compared with 5% on placebo. Among people with double vision, it improved in 59% with active disease and 56% with long-standing disease, compared with 20% and 25% on placebo. The benefit does not last for everyone. A year after starting, about 71% of people with active disease and 57% with long-standing disease who had responded still met the response mark. Some people continue to have eye changes afterward and discuss further options with their eye specialist. Hearing, blood sugar and any bowel symptoms are watched throughout the course, and hearing is checked again once it ends.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lumvoa (Veligrotug), what you've noticed, or ask the community a question.